Although many antibody-engineering labs are focused on translational work, most antibody-based therapeutics developed in academia, and many developed by small companies, either do not make it into clinical study or do not proceed past Phase 1. Few are ultimately licensed by large pharmaceutical firms because many antibodies developed in academic labs are not associated with sufficiently robust characteristics to allow successful commercial development.
In addition, academic labs and small biotech often encounter difficulty in securing funding for the development of clinical-grade material and subsequent clinical trials. Taking interesting laboratory discoveries to the next step is further hindered by a lack of knowledge about what venture capital (VC)/biotech/pharma companies are interested in, who to talk to, and how to make a deal. What makes a new antibody-based therapeutic sufficiently novel to attract interest?
This symposium is designed to bring together scientists and entrepreneurs who will share their experiences with successfully tackling these and other issues that block the clinical development of many antibody-based therapeutics.
8.00-8.35am Greg Adams (Sesen Bio)
• Introduction to The Antibody Society and the purpose of this symposium
• Why does this session matter to academic/biotech scientists who want to develop clinical agents?
8.35-9.10am Yingda Xu (Adimab)
• Designing and screening for the properties that decrease the risk of failure during clinical development of an antibody
• Screening for function, stability and specificity
9.10-9.45am Wayne Marasco (MGH/Harvard)
• Screening antibodies for clinically relevant function
• Investigator-initiated Phase 1 clinical studies
9.45-10.15am Coffee break
10.15-10.50am Jim Larrick (Panorama Research Institute, Velocity Pharmaceutical Development)
• Supporting clinical research with grant funding
• Taking a preclinical lead to the clinic
10.50-11.25am Patrick Baeuerle (MPM Capital)
• Bringing a new class of antibodies to the clinic
• Building a biotech
• Selling to pharma
• View from the VC world
11.25-12.00 Abbie Celniker (3rd Rock Ventures)
• Formation and development of VC-backed companies
• What does a VC look for:
o in a platform?
o In a scientific team?
• Learn about the history, contributions, and initiatives of The Antibody Society
• Learn what to do, and what not to do, when developing a therapeutic antibody in an academic or small biotech setting
• Learn how to partner with biopharmaceutical firms to take therapeutic antibody leads into the clinic or from Phase 1 to later-stage clinical studies